Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Block & Leviton LLP Investigates Hospira, Inc. for Possible Breaches of Fiduciary Duty in Connection with Their Proposed Acquisition by Pfizer Inc.

PFE

BOSTON, Feb. 5, 2015 /PRNewswire/ -- Block & Leviton LLP (www.blockesq.com), a law firm representing shareholders nationwide, with offices in Boston and the San Francisco Bay area, is investigating possible breaches of fiduciary duty by the Board of Directors of Hospira, Inc. ("Hospira" or the "Company") (NYSE: HSP) concerning the proposed acquisition of the Company by Pfizer Inc. ("Pfizer") (NYSE: PFE).  Hospira,is a provider of injectable drugs and infusion technologies that it develops, manufactures, distributes and markets globally. Its portfolio includes generic injectables, biosimilars, and integrated infusion therapy and medication management products. 

According to Reuters, "[d]rugmakers are racing to develop biosimilars, which typically cost 20-30 percent less than the original, as big-ticket patents on biotech drugs expire and cash-strapped healthcare systems look to cut costs.  Biosimilars are expected to account for about a quarter of the $100 billion in sales stemming from off-patent biological drugs by the end of the decade …."  Hospira is uniquely situated in this market because it was one of the first U.S. drug makers providing biosimilars to patients in Europe and Australia.

Under the terms of the proposed transaction, shareholders of the Company will receive $90.00 per share, representing a premium of just 39%. This transaction appears to be far below that received in recent similar industry transactions. Hospira's stock price has surged over the last 3 months.  According to the companies, the transaction will close in the second half of 2015.

Block & Leviton's investigation seeks to determine, among other things, whether directors of the Company breached their fiduciary duties by failing to maximize shareholder value in the potential acquisition and the process by which the directors considered and approved the transaction.  The investigation also seeks to determine whether Pfizer aided and abetted the Company's potential breach of fiduciary duty.

If you are a shareholder of Hospira and have questions about your legal rights, or if you have information relevant to this investigation, please contact attorney Steven P. Harte, at (617) 398-5600 or email him at Steven@blockesq.com.

Block & Leviton is a national law firm that represents consumers throughout the United States. The firm's lawyers have collectively been representing plaintiffs for decades. This notice may constitute attorney advertising.

Contact:
BLOCK & LEVITON LLP
Steven P. Harte, Esq.
steven@blockesq.com
(617) 398-5600

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/block--leviton-llp-investigates-hospira-inc-for-possible-breaches-of-fiduciary-duty-in-connection-with-their-proposed-acquisition-by-pfizer-inc-300031530.html

SOURCE Block & Leviton LLP